{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:33:32Z","timestamp":1784918012232,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s11102-023-01362-z","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T06:02:01Z","timestamp":1700805721000},"page":"33-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Newer parameters of the octreotide test in patients with acromegaly"],"prefix":"10.1007","volume":"27","author":[{"given":"Shin","family":"Urai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7000-8134","authenticated-orcid":false,"given":"Masaaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Shichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Kanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genzo","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"1362_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST et al (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10:804\u2013826. https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1362_CR2","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A et al (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 105:e937\u2013e946. https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14:552\u2013561. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"key":"1362_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1210\/jc.2014-2468","volume":"100","author":"D Cuevas-Ramos","year":"2015","unstructured":"Cuevas-Ramos D, Carmichael JD, Cooper O et al (2015) A structural and functional acromegaly classification. J Clin Endocrinol Metab 100:122\u2013131. https:\/\/doi.org\/10.1210\/jc.2014-2468","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR5","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","volume":"99","author":"JD Carmichael","year":"2014","unstructured":"Carmichael JD, Bonert VS, Nu\u00f1o M et al (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 99:1825\u20131833. https:\/\/doi.org\/10.1210\/jc.2013-3757","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","volume":"24","author":"MR Gadelha","year":"2013","unstructured":"Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24:238\u2013246. https:\/\/doi.org\/10.1016\/j.tem.2012.11.007","journal-title":"Trends Endocrinol Metab"},{"key":"1362_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU et al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24:1\u201313. https:\/\/doi.org\/10.1007\/s11102-020-01091-7","journal-title":"Pituitary"},{"key":"1362_CR8","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","volume":"107","author":"M-D Ilie","year":"2022","unstructured":"Ilie M-D, Tabarin A, Vasiljevic A et al (2022) Predictive factors of somatostatin receptor ligand response in acromegaly\u2014a prospective study. J Clin Endocrinol Metab 107:2982\u20132991. https:\/\/doi.org\/10.1210\/clinem\/dgac512","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2265.1988.tb02890.x","volume":"29","author":"SW Lamberts","year":"1988","unstructured":"Lamberts SW, Uitterlinden P, Schuijff PC, Klijn JG (1988) Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical \u201ccure.\u201d Clin Endocrinol 29:411\u2013420. https:\/\/doi.org\/10.1111\/j.1365-2265.1988.tb02890.x","journal-title":"Clin Endocrinol"},{"key":"1362_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cen.12731","volume":"83","author":"M Puig Domingo","year":"2015","unstructured":"Puig Domingo M (2015) Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol 83:3\u201314. https:\/\/doi.org\/10.1111\/cen.12731","journal-title":"Clin Endocrinol"},{"key":"1362_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/clinem\/dgab726","volume":"107","author":"MR Gadelha","year":"2022","unstructured":"Gadelha MR, Wildemberg LE, Kasuki L (2022) The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 107:297\u2013308. https:\/\/doi.org\/10.1210\/clinem\/dgab726","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1365-2265.2005.02278.x","volume":"62","author":"JA Gilbert","year":"2005","unstructured":"Gilbert JA, Miell JP, Chambers SM et al (2005) The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol 62:742\u2013747. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02278.x","journal-title":"Clin Endocrinol"},{"key":"1362_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-2008-1065339","volume":"40","author":"I Halperin","year":"2008","unstructured":"Halperin I, Nicolau J, Casamitjana R et al (2008) A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Horm Metab Res 40:422\u2013426. https:\/\/doi.org\/10.1055\/s-2008-1065339","journal-title":"Horm Metab Res"},{"key":"1362_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1590\/s0004-27302005000300010","volume":"49","author":"GF Taboada","year":"2005","unstructured":"Taboada GF, Donangelo I, Guimar\u00e3es RFC et al (2005) Acute test with subcutaneous octreotide as a predictor of the response to treatment with octreotide LAR. Arq Bras Endocrinol Metabol 49:390\u2013395. https:\/\/doi.org\/10.1590\/s0004-27302005000300010","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"1362_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/eje.1.01935","volume":"153","author":"WW de Herder","year":"2005","unstructured":"de Herder WW, Taal HR, Uitterlinden P et al (2005) Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol 153:67\u201371. https:\/\/doi.org\/10.1530\/eje.1.01935","journal-title":"Eur J Endocrinol"},{"key":"1362_CR16","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1210\/jc.2008-0424","volume":"93","author":"A Colao","year":"2008","unstructured":"Colao A, Pivonello R, Auriemma RS et al (2008) Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. J Clin Endocrinol Metab 93:3436\u20133442. https:\/\/doi.org\/10.1210\/jc.2008-0424","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1210\/er.2010-0002","volume":"32","author":"A Colao","year":"2011","unstructured":"Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247\u2013271. https:\/\/doi.org\/10.1210\/er.2010-0002","journal-title":"Endocr Rev"},{"key":"1362_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","volume":"23","author":"S Petersenn","year":"2020","unstructured":"Petersenn S, Houchard A, Sert C et al (2020) Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary 23:171\u2013181. https:\/\/doi.org\/10.1007\/s11102-019-01020-3","journal-title":"Pituitary"},{"key":"1362_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12020-023-03317-7","volume":"80","author":"A Giustina","year":"2023","unstructured":"Giustina A, di Filippo L, Uygur MM, Frara S (2023) Modern approach to resistant acromegaly. Endocrine 80:303\u2013307. https:\/\/doi.org\/10.1007\/s12020-023-03317-7","journal-title":"Endocrine"},{"key":"1362_CR20","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","volume":"77","author":"A Heck","year":"2012","unstructured":"Heck A, Ringstad G, Fougner SL et al (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol 77:72\u201378. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04286.x","journal-title":"Clin Endocrinol"},{"key":"1362_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1148\/radiol.2282020695","volume":"228","author":"A Hagiwara","year":"2003","unstructured":"Hagiwara A, Inoue Y, Wakasa K et al (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228:533\u2013538. https:\/\/doi.org\/10.1148\/radiol.2282020695","journal-title":"Radiology"},{"key":"1362_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1507\/endocrj.ej12-0110","volume":"59","author":"T Isojima","year":"2012","unstructured":"Isojima T, Shimatsu A, Yokoya S et al (2012) Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 59:771\u2013780. https:\/\/doi.org\/10.1507\/endocrj.ej12-0110","journal-title":"Endocr J"},{"key":"1362_CR24","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1210\/jcem.81.6.8964877","volume":"81","author":"A Colao","year":"1996","unstructured":"Colao A, Ferone D, Lastoria S et al (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81:2356\u20132362. https:\/\/doi.org\/10.1210\/jcem.81.6.8964877","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11102-014-0580-y","volume":"18","author":"M Yamamoto","year":"2015","unstructured":"Yamamoto M, Fukuoka H, Iguchi G et al (2015) The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study. Pituitary 18:343\u2013351. https:\/\/doi.org\/10.1007\/s11102-014-0580-y","journal-title":"Pituitary"},{"key":"1362_CR26","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1210\/clinem\/dgaa387","volume":"105","author":"EC Coopmans","year":"2020","unstructured":"Coopmans EC, Korevaar TIM, van Meyel SWF et al (2020) Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 105:2964\u20132974. https:\/\/doi.org\/10.1210\/clinem\/dgaa387","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036411","volume":"7","author":"A Giustina","year":"2012","unstructured":"Giustina A, Mazziotti G, Torri V et al (2012) Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7:e36411. https:\/\/doi.org\/10.1371\/journal.pone.0036411","journal-title":"PLoS ONE"},{"key":"1362_CR28","doi-asserted-by":"publisher","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","volume":"98","author":"O Casar-Borota","year":"2013","unstructured":"Casar-Borota O, Heck A, Schulz S et al (2013) Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab 98:E1730\u2013E1739. https:\/\/doi.org\/10.1210\/jc.2013-2145","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1507\/endocrj.EJ16-0175","volume":"63","author":"M Wang","year":"2016","unstructured":"Wang M, Shen M, He W et al (2016) The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly. Endocr J 63:819\u2013834. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0175","journal-title":"Endocr J"},{"key":"1362_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1365-2265.2004.02191.x","volume":"62","author":"N Karavitaki","year":"2005","unstructured":"Karavitaki N, Botusan I, Radian S et al (2005) The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol 62:282\u2013288. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02191.x","journal-title":"Clin Endocrinol"},{"key":"1362_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1756-9966-32-40","volume":"32","author":"A Bianchi","year":"2013","unstructured":"Bianchi A, Valentini F, Iuorio R et al (2013) Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res 32:40. https:\/\/doi.org\/10.1186\/1756-9966-32-40","journal-title":"J Exp Clin Cancer Res"},{"key":"1362_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12020-022-03158-w","volume":"78","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Costa D, Lauretta R et al (2022) Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine 78:343\u2013353. https:\/\/doi.org\/10.1007\/s12020-022-03158-w","journal-title":"Endocrine"},{"key":"1362_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-20-0767","volume":"184","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Mirra F et al (2021) Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol 184:217\u2013229. https:\/\/doi.org\/10.1530\/EJE-20-0767","journal-title":"Eur J Endocrinol"},{"key":"1362_CR34","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875\u2013884. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1362_CR35","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1210\/jc.2003-030110","volume":"88","author":"R Cozzi","year":"2003","unstructured":"Cozzi R, Attanasio R, Montini M et al (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090\u20133098. https:\/\/doi.org\/10.1210\/jc.2003-030110","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228\u2013252. https:\/\/doi.org\/10.1016\/j.yfrne.2013.07.005","journal-title":"Front Neuroendocrinol"},{"key":"1362_CR37","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1210\/jc.2008-0315","volume":"93","author":"SM Carlsen","year":"2008","unstructured":"Carlsen SM, Lund-Johansen M, Schreiner T et al (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93:2984\u20132990. https:\/\/doi.org\/10.1210\/jc.2008-0315","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR38","doi-asserted-by":"publisher","first-page":"668","DOI":"10.4158\/EP14575.DSCR","volume":"21","author":"M Fleseriu","year":"2015","unstructured":"Fleseriu M, Hoffman AR, Katznelson L, Neuroendocrine AACE, Committee PS (2015) American association of clinical endocrinologists and American college of endocrinology disease state clinical review: management of acromegaly patients: what is the role of pre-operative medical therapy? Endocr Pract 21:668\u2013673. https:\/\/doi.org\/10.4158\/EP14575.DSCR","journal-title":"Endocr Pract"},{"key":"1362_CR39","doi-asserted-by":"publisher","first-page":"14070","DOI":"10.1038\/s41598-019-50639-6","volume":"9","author":"C Yang","year":"2019","unstructured":"Yang C, Li G, Jiang S et al (2019) Preoperative somatostatin analogues in patients with newly-diagnosed acromegaly: a systematic review and meta-analysis of comparative studies. Sci Rep 9:14070. https:\/\/doi.org\/10.1038\/s41598-019-50639-6","journal-title":"Sci Rep"},{"key":"1362_CR40","doi-asserted-by":"publisher","first-page":"bvac114","DOI":"10.1210\/jendso\/bvac114","volume":"6","author":"F Albarel","year":"2022","unstructured":"Albarel F, Cuny T, Graillon T et al (2022) Preoperative medical treatment for patients with acromegaly: yes or no? J Endocr Soc 6:bvac114. https:\/\/doi.org\/10.1210\/jendso\/bvac114","journal-title":"J Endocr Soc"},{"key":"1362_CR41","doi-asserted-by":"publisher","first-page":"E373","DOI":"10.1210\/jc.2009-2556","volume":"95","author":"AF Daly","year":"2010","unstructured":"Daly AF, Tichomirowa MA, Petrossians P et al (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95:E373\u2013E383. https:\/\/doi.org\/10.1210\/jc.2009-2556","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR42","doi-asserted-by":"publisher","first-page":"E1411","DOI":"10.1210\/jc.2012-1111","volume":"97","author":"HS Chahal","year":"2012","unstructured":"Chahal HS, Trivellin G, Leontiou CA et al (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 97:E1411\u2013E1420. https:\/\/doi.org\/10.1210\/jc.2012-1111","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fendo.2015.00187","volume":"6","author":"E Peverelli","year":"2015","unstructured":"Peverelli E, Treppiedi D, Giardino E et al (2015) Dopamine and somatostatin analogues resistance of pituitary tumors: focus on cytoskeleton involvement. Front Endocrinol 6:187. https:\/\/doi.org\/10.3389\/fendo.2015.00187","journal-title":"Front Endocrinol"},{"key":"1362_CR44","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-15-0391","volume":"174","author":"F Gatto","year":"2016","unstructured":"Gatto F, Biermasz NR, Feelders RA et al (2016) Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol 174:651\u2013662. https:\/\/doi.org\/10.1530\/EJE-15-0391","journal-title":"Eur J Endocrinol"},{"key":"1362_CR45","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1210\/jc.2009-2197","volume":"95","author":"SL Fougner","year":"2010","unstructured":"Fougner SL, Lekva T, Borota OC et al (2010) The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab 95:2334\u20132342. https:\/\/doi.org\/10.1210\/jc.2009-2197","journal-title":"J Clin Endocrinol Metab"},{"key":"1362_CR46","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.3390\/ijms24032875","volume":"24","author":"DG Henriques","year":"2023","unstructured":"Henriques DG, Miranda RL, Dezonne RS et al (2023) miR-383-5p, miR-181a-5p, and miR-181b-5p as predictors of response to first-generation somatostatin receptor ligands in acromegaly. Int J Mol Sci 24:2875. https:\/\/doi.org\/10.3390\/ijms24032875","journal-title":"Int J Mol Sci"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01362-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01362-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01362-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T05:17:12Z","timestamp":1706851032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01362-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1362"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01362-z","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"assertion":[{"value":"23 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conformed to the Declaration of Helsinki guideline and was approved by the ethics committee of Kobe University Graduate School of Medicine (Approval No. 1363).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the participants using an opt-out approach.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}